Full Press Release Details
BridgeBio Pharma Closes $299.2 Million Financing Round To Support Its Efforts To Target Genetic Disease At The Source.
BBIO
BridgeBio Pharma Closes $299.2 Million Financing Round To Support Its Efforts To Target Genetic Disease At The Source
Key Takeaway: BridgeBio Pharma Closes $299.2 Million Financing Round To Support Its Efforts To Target Genetic Disease At The Source
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis